PAVmed (PAVM) AI Stock Analysis

• Market Cap: $7.46M
• Dividend Yield: N/A
• Average Volume (3M): 213.47K
• Price to Earnings (P/E): 0.4
• Beta (1Y): 1.67
• Revenue Growth: -73.36%
• EPS Growth: N/A
• Country: US
• Employees: 39
• Sector: Healthcare
• Sector Strength: 50
• Industry: Medical - Devices
• EPS (TTM): -0.74
• Shares Outstanding: 17,294,619
• 10 Day Avg. Volume: 418,946
• 30 Day Avg. Volume: 213,472
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 4.64
• Enterprise Value/Revenue: 4.94
• Enterprise Value/Gross Profit: -0.98
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: $7.17
• Price Target Upside: 1567.44% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 46 Neutral
• Price Target: $0.50 ▲(16.28% Upside)

PAVmed's overall stock score is primarily impacted by its financial challenges, including negative margins and liquidity risks. While technical indicators and valuation suggest potential, the company's strategic initiatives and recent corporate events provide some positive outlook. Addressing profitability and operational efficiency will be crucial for future growth.

Positive Factors

Commercialization Growth

Lucid Diagnostics reported strong EsoGuard testing results and is expected to receive Medicare coverage, which could drive further growth.

Product Development

Veris Health resumed development of its implantable physiological monitor and plans an FDA submission, showing advancement in product development.

Strategic Partnerships

PAVM entered into a strategic partnership agreement with The Ohio State University Comprehensive Cancer Center to advance the Veris Health platform.

Negative Factors

Development and Commercialization Challenges

PAVmed’s devices still have long development and commercialization challenges ahead, but the ~billion dollars market potential presents high rewards for the risks.

Revenue Challenges

Revenue estimates for 2025 and 2026 have been lowered due to a slower expected ramp in patients.

Technology Challenges

Technology integration challenges may delay patient enrollment and weigh on top-line growth through 2026.

PAVmed Business Overview & Revenue Model

Company Description

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

How the Company Makes Money

PAVmed generates revenue through the sales of its medical devices and diagnostic products to hospitals, clinics, and healthcare providers. The company's revenue model is primarily based on direct sales and distribution agreements, allowing it to reach a wide range of customers. Key revenue streams include product sales from its innovative devices, potential licensing agreements, and partnerships with healthcare organizations that facilitate the adoption of its technologies. Additionally, PAVmed may benefit from reimbursement policies for its products, which can enhance sales and overall revenue growth.

PAVmed Financial Statement Overview

Summary

PAVmed's financial health faces significant challenges. Despite revenue growth, the company reports persistent operational losses and cash flow difficulties. The balance sheet shows improvement, but high leverage remains a concern.

Income Statement

PAVmed's income statement reveals substantial challenges. The TTM (Trailing-Twelve-Months) data shows a negative gross profit margin and EBIT margin, indicating significant operational losses. Despite a remarkable increase in total revenue, net income remains highly volatile, underscored by a net profit margin that is skewed due to a large net income figure possibly influenced by extraordinary items. The revenue growth rate is impressive but is overshadowed by persistent negative profitability margins.

Balance Sheet

The balance sheet presents a mixed picture. While total assets have grown significantly, the debt-to-equity ratio is concerning, with substantial negative equity in previous years turning positive this year. The equity ratio has improved, suggesting better asset management, but the high total liabilities relative to equity indicate potential risks. Overall, financial stability appears fragile despite recent improvements.

Cash Flow

Cash flow analysis indicates that PAVmed struggles with cash generation. Operating cash flow is negative in the TTM period, reflecting operational inefficiencies. The free cash flow remains negative, highlighting issues in converting revenue into cash. Although there are significant financing inflows, reliance on external financing remains high. The operating cash flow to net income ratio is unfavorable, suggesting a disconnect between accounting profits and cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.01M	3.00M	2.45M	377.00K	500.00K	0.00
Gross Profit	-35.49M	-3.04M	-3.97M	-3.24M	-85.00K	-23.00K
EBITDA	-4.63B	29.67M	-75.74M	-99.41M	-55.90M	-35.81M
Net Income	-13.22B	39.79M	-64.17M	-88.98M	-50.35M	-34.33M
Balance Sheet
Total Assets	43.89B	30.66M	33.12M	53.98M	86.98M	19.78M
Cash, Cash Equivalents and Short-Term Investments	4.00B	1.19M	19.64M	39.74M	77.26M	17.26M
Total Debt	9.31B	31.86M	48.73M	36.64M	0.00	14.96M
Total Liabilities	12.47B	37.69M	57.14M	43.05M	7.56M	20.25M
Stockholders Equity	37.53B	-2.50M	-53.83M	-9.68M	61.67M	1.90M
Cash Flow
Free Cash Flow	-2.77B	-33.61M	-52.28M	-72.53M	-42.06M	-21.97M
Operating Cash Flow	-2.77B	-33.55M	-52.04M	-70.98M	-40.59M	-21.91M
Investing Cash Flow	-30.14M	-16.18M	758.00K	-4.74M	-3.72M	-55.00K
Financing Cash Flow	2.49B	31.28M	31.17M	38.21M	104.31M	33.01M

PAVmed Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAVM, the sentiment is Negative. The current price of 0.43 is below the 20-day moving average (MA) of 0.50, below the 50-day MA of 0.57, and below the 200-day MA of 0.70, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 32.32 is Neutral, neither overbought nor oversold. The STOCH value of 64.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PAVM.

PAVmed Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	€2.53B	13.48	-8.75%	2.44%	23.33%	-34.45%
TNON	53 Neutral	$12.34M	―	-335.48%	―	-12.60%	95.87%
HSCS	50 Neutral	$7.59M	―	-233.04%	―	-76.61%	73.25%
BMRA	49 Neutral	$8.07M	―	-72.70%	―	5.05%	26.13%
PAVM	46 Neutral	$7.46M	0.37	-499.57%	―	-73.36%	―
SSKN	45 Neutral	$7.59M	―	-235.41%	―	0.36%	-17.20%
CODX	45 Neutral	$12.33M	―	-63.40%	―	-91.14%	9.47%

PAVmed Corporate Events

PAVmed Reports Q2 2025 Financial Results and Developments

In its second quarter of 2025, PAVmed Inc. reported significant business developments and financial results. Lucid Diagnostics processed 2,756 EsoGuard tests, generating $1.2 million in revenue, and secured a Medicare LCD meeting for September 4, 2025. Veris Health completed financing and is advancing its implantable monitor towards FDA clearance, with strategic partnerships in place to enhance its commercial deployment. PAVmed’s financial results showed a GAAP net loss of $13.3 million, with a strengthened balance sheet and cash reserves of $4.0 million as of June 30, 2025.

The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

PAVmed Granted Nasdaq Extension for Compliance

On July 29, 2025, PAVmed Inc. received a notification from Nasdaq granting an additional 180 days, until January 19, 2026, to comply with the minimum bid price requirement of $1 per share. The company had initially been given until July 22, 2025, to meet this requirement but failed to do so. Despite this, Nasdaq has allowed an extension, and PAVmed plans to explore all options to regain compliance. The company’s stock will continue to trade under the symbol ‘PAVM’ without interruption.

The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

PAVmed’s Veris Health Completes $2.5M Offering

On June 23, 2025, Veris Health Inc., a subsidiary of PAVmed Inc., completed a $2.5 million offering by selling shares and warrants to accredited investors, aimed at funding the development of its implantable physiological monitor and general operations. This strategic move enhances Veris’ financial position and provides investors with future participation rights, potentially strengthening its market presence and operational capabilities.

The most recent analyst rating on (PAVM) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

PAVmed Holds Annual Stockholders Meeting, Approves Key Proposals

On June 18, 2025, PAVmed Inc. held its annual meeting of stockholders, where approximately 77.2% of shares were represented. During the meeting, stockholders elected management’s nominees for director, approved the issuance of common stock upon exercise of pre-funded warrants, amended the 2014 Long-Term Incentive Equity Plan to increase available shares, approved executive compensation, and ratified the appointment of Marcum LLP as the independent registered certified public accounting firm for 2025.

The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

PAVmed Reports Q1 2025 Financial Results and Updates

On May 15, 2025, PAVmed Inc. provided a business update and reported its first-quarter financial results for 2025. Lucid Diagnostics secured capital to extend its runway beyond key reimbursement milestones and reported $0.8 million in revenue from its EsoGuard Esophageal DNA Test. Veris Health resumed development of its implantable physiological monitor and is set to launch a commercial partnership with a major cancer center. PAVmed is actively seeking to expand into the biopharma sector, evaluating clinical and late preclinical-stage assets. Financially, PAVmed ended the first quarter with over $40 million in pro forma cash, and its operating expenses were approximately $5.5 million, resulting in a GAAP net income of $17.7 million.

The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.